The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study

Ishimitsu, Toshihiko; Fukuda, Hirofumi; Uchida, Masayuki; Ishibashi, Kazushi; Sato, Fusako; Nukui, Kazuhiko; Nagao, Munehiko

doi:10.3109/10641963.2015.1026037

Cited by 7 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ishimitsu et al [ 30 ] conducted a prospective clinical survey examining the efficacy and safety of 12-week treatment with amlodipine and an ARB in 5900 patients with AH. The combination antihypertensive therapy with amlodipine and ARB effectively lowered blood pressure and reduced SU [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Nieradko-Iwanicka

2018

Reumatologia

View full text Add to dashboard Cite

Angiotensin receptor blockers or sartans are used to treat arterial hypertension. Hyperuricemia and arterial hypertension often coexist in patients with metabolic syndrome. Also hyperuricemia is correlated with an increased risk of cardiovascular disease and death. There are data suggesting that lowering serum urate may assist in control of arterial hypertension and use of certain drugs for arterial hypertension may reduce the serum uric acid level. The Polish Society of Arterial Hypertension recommends losartan for treatment of arterial hypertension in patients with coexisting hyperuricemia.The aim of the present review was to find evidence supporting the concept of use and explain the role of sartans in treatment of hyperuricemia.Thirty-five original and review articles about hyperuricemia and arterial hypertension focusing on the use of sartans in both these medical conditions were analyzed.In conclusion, sartans should be recommended for treatment of hyperuricemia coexisting with arterial hypertension in patients without bilateral renal artery stenosis and with exclusion of pregnant women.

show abstract

Section: Discussionmentioning

confidence: 99%

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Nieradko-Iwanicka

2018

Reumatologia

View full text Add to dashboard Cite

show abstract

“…Además, la proporción de pacientes que alcanzaron el control de la PA a través del período de tratamiento fue del 62.7% (IC 99%: 57.5-68.6%), que se aproxima al objetivo establecido por la OPS del 70% de pacientes tratados para el 2019 8 . Los resultados observados en este estudio concuerdan con los resultados del estudio PARTNER, el cual demostró una alta efectividad terapéutica de amlodipino/irbesartán en combinación fija para el tratamiento de la hipertensión 26 .…”

Section: Discussionunclassified

Real-life effectiveness and safety of fixed amlodipine/irbesartan in hypertension management in Latin America: the PARCERIA study

Ruiz,

Funes,

Higa

et al. 2024

RCCAR

View full text Add to dashboard Cite

Introduction: Latin American population-based studies have shown suboptimal blood pressure control rates. Fixed-dose anti-hypertensive combinations are associated with improved convenience, adherence and effectiveness compared with monotherapy. Objective: assessed the real-life effectiveness and safety of fixed amlodipine/irbesartan combination in long-term management of hypertension in Argentina, Chile, Colombia, Guatemala, and Mexico. Materials and method: this was a 48-week, prospective, observational, single-cohort study, which included adults with uncontrolled hypertension, treated with fixed amlodipine/irbesartan combination per the treating physician's judgment, were followed in routine care. Target blood pressure was < 140/90 mmHg (< 130/80 mmHg for patients with diabetes or renal disease). Results: 509 patients (57.6% females) were included. Mean (SD) age and Framingham 10-year risk-score were 60.6 (12.5) years and 9.9 (8.78), respectively. Over 48 weeks, 97.4% of patients took ≥ 80% of prescribed doses. Statistically significant and clinically important blood pressure improvements (-25.7/-13.5 mmHg; p < 0.001) were observed. Control was achieved by 62.7% of patients. Treatment compliance was one of the significant (p < 0.05) predictors of target blood pressure achievement. Eighty-seven (17.1%) patients experienced 117 treatment-emergent adverse events, including 7 serious events by 5 (1.0%) patients. Adverse events were generally mild (75.2%) and judged not to be treatment-related (76.1%). The most common adverse events were peripheral edema (3.9% of patients) and dizziness (1.0%). Based on Kaplan-Meier estimates, the mean (SE) time to adverse event-related discontinuation was 32.85 (0.08) weeks. Conclusion: Treatment with the fixed-dose combination of irbesartan/amlodipine demonstrated clinical effectiveness, with a significant improvement in blood pressure values and a higher rate of achieving the treatment goal in those who adhered to the regimen. The treatment was well-tolerated, with a low percentage of treatment-related adverse events, and few severe events. The fixed-dose combination is an important tool in the management of arterial hypertension.

show abstract

“…Calcium channel blockers (CCB) are an indispensable category of anti-hypertensive drugs [28]. Nifedipine is a calcium channel blocker that is widely used in clinics [29].…”

Section: Discussionmentioning

confidence: 99%

Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease

Wang¹,

Yu²,

Yang³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This study aimed to examine the interaction between these two types of medication on the endothelial cell function. Methods: The effect of antihypertensive (nifedipine and irbesartan) and anti-diabetic (metformin and glibenclamide/glimepiride) drugs on human umbilical vein cells (HUVECs) function was examined using a modified Boyden chamber assay. The intracellular NO and O₂^- levels of HUVECs were detected through flow cytometry. Results: Our findings showed that nifedipine/sulphonylurea monotherapy significantly attenuated high glucose-induced (33 mM) HUVECs migration incapacity, while combination therapy of nifedipine and glibenclamide/glimepiride showed no protective effect. Both nifedipine/metformin monotherapy and combined therapy significantly mitigated the migration incapacity induced by high glucose in HUVECs. Combined with either metformin or sulphonylureas, irbesartan therapy was able to attenuate the high glucose-induced migration incapacity of HUVECs. Nifedipine monotherapy decreased the O₂^- levels and increased the NO levels in in vitro-cultured HUVECs treated with high glucose. However, the combination therapy of nifedipine and glibenclamide increased the O₂^- levels and decreased the NO levels compared to the nifedipine monotherapeutic group. Conclusion: The nifedipine and glibenclamide/glimepiride combination exerted a mutual antagonistic effect on the protection from high glucose-induced impairment in endothelial cells, which might be partially attributed to the increased O₂^- level and decreased NO level. These results imply that calcium channel blockers + sulphonylurea combination therapy warrants further attention in patients suffering from both hypertension and diabetes.

show abstract

Cited by 7 publications

References 28 publications

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Real-life effectiveness and safety of fixed amlodipine/irbesartan in hypertension management in Latin America: the PARCERIA study

Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease

Contact Info

Product

Resources

About